Skip to Main Content
Qurgen Qurgen
Menu Button

Clinical Pipeline

Qurgen is investing in scientific and technical excellence for developing a pipeline of innovative medicines that combat cancer, heart failure, diabetes, eye diseases and anti-aging.

Clinical Pipeline

On December 7, 2022, the US FDA granted a first-in-human Phase I clinical trial IND approval for our leading anti-cancer transcription factor drug, “SON-DP” to treat late-stage solid tumors with the focus on breast, ovarian, pancreatic and colorectal cancers (IND Number: 152226, ClinicalTrials.gov ID: NCT05989724). We had engaged with the following 5 hospitals for this clinical trial in US for Phase Ia dose escalation stage:

  1.  MD Anderson Cancer Center
  2.  Henry Ford Health System
  3.  Carolina BioOncology Institute (CBI)
  4. Banner MD Anderson at Banner Gateway Medical Center
  5. Stephenson Cancer Center, University of Oklahoma

Qurgen has also obtained IRB approvals for this Phase I clinical trial of SON-DP. The first patient has undergone treatment in September of 2023. Up to August of 2024, our clinical data demonstrated the safety of SON-DP drug and also displayed initial efficacy data of tumor shrinkage and disappearance of smaller metastatic lessons in late-stage solid tumor patients at the mid-dose levels of SON-DP drug.

Please click here to view this clinical trial.

Clinical Pipeline and Development Plan of TF protein drugs

Cancer is a major disease that poses a severe threat to human health. The R&D of anti-tumor drugs represents the earliest and most advanced business segment of Qurgen. The oncology project initiated preclinical research in 2020, obtained clinical trial approval in 2024, and is currently in Phase II clinical trials.  

Research on aging is of important scientific value and practical significance for prolonging human healthy lifespan, preventing and treating aging-related diseases, improving the quality of life of the elderly, and alleviating the social elderly care burden. In particular, given the accelerating population aging process in China, conducting research on aging mechanisms and promoting the development of the anti-aging industry have become an urgent need.Our company launched the preclinical research of the anti-aging program in 2023. Current research results show that the conception rate of the administration group was 6.5 times higher than that of the control group in 22-month-old aged rats. Analysis of aortic aging also demonstrated that the administration group outperformed the control group. The preclinical findings mark a major breakthrough in our innovative anti-aging drug development.

As a progressive and irreversible pulmonary disease, pulmonary fibrosis leads to continuous decline in lung function, respiratory failure and even death. Current clinical drugs such as Pirfenidone and Nintedanib can only slow down disease progression and cannot achieve fundamental reversal.Therefore, research on anti-pulmonary fibrosis drugs helps to explore safer and more effective therapeutic strategies, reduce the burden on patients, and improve their prognosis and quality of life.Since 2023, our company has carried out basic research on pulmonary fibrosis. We adopt a bleomycin-induced rat pulmonary fibrosis animal model to evaluate the therapeutic effect of our protein drug on pulmonary fibrosis.
Diabetes has become a major challenge in the field of global public health. Currently, its epidemic situation continues to spread, and the age of onset shows an obvious younger trend. Therefore, breakthrough scientific research progress is urgently needed in key areas such as elucidating the pathogenesis of diabetes, developing precise diagnosis and treatment technologies, early prevention and control of complications, and full-cycle health management.
Our company adopts protein delivery technology to conduct therapeutic research using diabetic model mice. The existing results show that both random blood glucose and fasting blood glucose in the model mice decreased significantly, and we are further advancing the preclinical research.
Cardiovascular diseases are the leading cause of mortality and disability worldwide. Myocardial infarction (MI), which triggers extensive death of cardiomyocytes, endothelial cells and fibroblasts due to myocardial ischemia, is one of the most severe types of cardiovascular diseases.
The hearts of humans and mammals possess a regenerative repair barrier, resulting in limited cardiac repair capacity. Therefore, the regeneration and repair mechanism of cardiomyocytes during cardiac repair represents a research frontier and key focus in the field of regenerative medicine.Since 2020, our company has been exploring therapies for ischemic heart failure. At present, treatment studies in heart failure model organisms including beagle dogs and rats have demonstrated significant improvement in cardiac function and reduced levels of cardiac fibrosis after myocardial infarction.
Clinical Pipeline

In addition to our anti-cancer drug, SON-DP, which is at a Phase I clinical trial stage in the US and soon in China with the focuses on breast, ovary, pancreatic and colorectal cancers in the US and liver and stomach cancers in China, Qurgen has also developed several transcription factor drugs for the treatment of heart failure, diabetes, eye disease (eye drops) and anti-aging. Qurgen anticipates to applying a first-in-human Phase I clinical trial in 2025 for its anti-heart failure drug, REPROGRAHT and anti-eye disease eye drop, REPROGREYES.

Follow Qurgen News

Learn More